Skip to main content

Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions

  • Salvatore Gentile (a1)

Beyond its formal indications (epilepsy, bipolar disorder, and migraine), valproate sodium (VPA) is widely used in a number of other clinical conditions. Recently, however, the U.S. Food and Drug Administration (FDA) issued a warning regarding a decrease in IQ scores in children prenatally exposed to the drug. For patients with migraine, the pregnancy labeling of VPA will be changed from Category “D” to “X.” VPA products will remain in pregnancy category “D” for treating epilepsy and manic episodes associated with bipolar disorder. Thus, this article aims to assess (through a computerized Medline/PubMed search) the neurobehavioral teratogenicity of valproate monotherapy, in order to evaluate alternative regulatory decisions. Reviewed information suggests a detrimental impact of antenatal valproate exposure on the global child neurodevelopment. Affected areas include not just reduced IQ scores, but also behavioral problems and a potential increase in the risk for a future diagnosis of attention-deficit/hyperactivity disorder. An increased risk of developing autism-spectrum disorders has also been reported. Thus, in my opinion, VPA should be assigned definitively to the Category “X,” independent of any considerations about its clinical indications, and should be strictly avoided during pregnancy, due to the demonstrated risk of both neurobehavioral and neurocognitive teratogenicity.

Corresponding author
*Address for correspondence: Salvatore Gentile, Department of Mental Health, ASL Salerno, Mental Health Centre n. 63 Cava de' Tirreni - Vietri Sul Mare, Piazza Galdi, 841013 Cava de’ Tirreni, Salerno, Italy. (Email:
Hide All
1.Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders--a population-based study of prescriptions. Epilepsy Res. 2009; 87(1): 3139.
2.Hayes J, Prah P, Nazareth I, etal. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995–2009. PLoS One. 2011; 6(12): e28725.
3.Barbui C, Conti V, Purgato M, etal. Use of antipsychotic drugs and mood stabilizers in women of childbearing age with schizophrenia and bipolar disorder: epidemiological survey. Epidemiol Psychiatr Sci. 2013; 22(4): 355361.
4.Adedinsewo DA, Thurman DJ, Luo YH, etal. Valproate prescriptions for nonepilepsy disorders in reproductive-age women. Birth Defects Res A Clin Mol Teratol. 2013; 97(6): 403408.
5.Gentile S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipolar Disord. 2006; 8(3): 207220.
6.Gentile S. Bipolar disorder and pregnancy: to treat or not to treat? BMJ. 2012; 345: e7367.
7.Vajda FJ, O'Brien TJ, Graham JE, Lander CM, Eadie MJ. Dose dependence of fetal malformations associated with valproate. Neurology. 2013; 81(11): 9991003.
8.Meador KJ. Comment: valproate dose effects differ across congenital malformations. Neurology. 2013; 81(11): 1002.
9.Pennell PB, Klein AM, Browning N, etal. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav. 2012; 24(4): 449456.
10.FDA Drug Safety Communication. Valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. Accessed: July 5, 2013.
11.Koch S, Titze K, Zimmermann RB, etal. Long-term epilepsy and neuropsychological consequences of maternal anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia. 1999; 40(9): 12371243.
12.Neurobehavioral Teratology Society. Accessed February 15, 2014.
13.Steinhausen HC, Losche G, Koch S, Helge H. The psychological development of children of epileptic parents. I. Study design and comparative findings. Acta Paediatr. 1994; 83(9): 955960.
14.Losche G, Steinhausen HC, Koch S, Helge H. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr. 1994; 83(9): 961966.
15.Koch S, Jäger-Roman E, Lösche G, etal. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatr. 1996; 84(6): 739746.
16.Adab N, Jacoby D, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2001; 70(1): 1521.
17.Dean CS, Hailey H, Moore SJ, etal. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet. 2002; 39(4): 251259.
18.Gaily E, Kantola-Sorsa E, Hiilesmaa V, etal. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology. 2004; 362(1): 2832.
19.Eriksson K, Viinikainen K, Monkkonen A, etal. Children exposed to valproate in utero—population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res. 2005; 65(3): 189200.
20.Viinikainen K, Eriksson K, Monkkonen A, etal. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy Behav. 2006; 9(4): 636640.
21.Thomas SV, Ajaykumar B, Sindhu K, etal. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav. 2008; 13(1): 229236.
22.Meador KJ, Baker GA, Browning N, etal. for the NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009; 360(16): 15971605.
23.McVearry KM, Gaillard WD, VanMeter J, Meador KJ. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav. 2009; 16(4): 609616.
24.Cohen MJ, Meador KJ, Browning N, etal. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral/functioning at age 3 years. Epilepsy Behav. 2011; 22(2): 240246.
25.Meador KJ, Baker GA, Browning N, etal. for the NEAD Study Group. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology. 2012; 78(16): 12071214.
26.Meador KJ, Baker GA, Browning N, etal. for the NEAD Study Group. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013; 12(3): 244252.
27.Cohen MJ, Meador KJ, Browning N, etal, for the NEAD study group. Fetal antiepileptic drug exposure: adaptive and emotional/behavioral functioning at age 6 years. Epilepsy Behav. 2013; 29(2): 308315.
28.Meador KJ, Baker GA, Browning N, etal, for the NEAD Study Group. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain. 2011; 134(Pt 2): 396404.
29.Adab N, Kini U, Vinten J, etal. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004; 75(11): 15751583.
30.Vinten J, Adab N, Kini U, etal, for the Liverpool and Manchester Neurodevelopment Study Group. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology. 2005; 64(6): 949954.
31.Vinten J, Bromley RL, Taylor J, etal, on behalf of the Liverpool and Manchester Neurodevelopment Group. The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy Behav. 2009; 14(1): 197201.
32.Bromley RL, Mawer G, Love J, etal, on behalf of the Liverpool and Manchester Neurodevelopment Group. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia. 2010; 51(10): 20582065.
33.Shallcross R, Bromley RL, Irwin B, etal, on behalf of the Liverpool/Manchester Neurodevelopment Group and the UK Epilepsy and Pregnancy Register. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology. 2011; 76(4): 383389.
34.Bromley RL, Mawer G, Clayton-Smith J, Baker GA, on behalf of the Liverpool and Manchester Neurodevelopment Group. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology. 2008; 71(28): 19231924.
35.Bromley RL, Mawer GE, Briggs M, etal, on Behalf of the Liverpool and Manchester Neurodevelopment Group.. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013; 84(6): 637643.
36.Johnson CP, Myers SM. American Academy of Pediatrics Council on Children with Disabilities. Identification and evaluation of children with autistic spectrum disorders. Pediatrics. 2007; 120(5): 11831215.
37.Nadebaum C, Anderson V, Vajda F, etal. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc. 2011; 17(1): 133142.
38.Nadebaum C, Anderson V, Vajda F, etal. Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology. 2011; 76(8): 719726.
39.Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child. 2011; 96(7): 643647.
40.Kantola-Sorsa E, Gaily E, Isoaho M, Korkman M. Neuropsychological outcomes in children of mothers with epilepsy. J Int Neuropsychol Soc. 2007; 13(4): 642652.
41.Christensen J, Grønborg TK, Sørensen MJ, etal. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013; 309(16): 16961703.
42.Veiby G, Daltvei AK, Schjølberg S, etal. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia. 2013; 54(8): 14621472.
43.Rosner B. Fundamentals of Biostatistics. Belmont, CA: Duxbury-Brooks/Cole; 2006.
44.Veiby G, Engelsen BA, Gilhus NE. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol. 2013; 70(11): 13671374.
45.Thomas JM, Benham AL, Gean M, etal. Practice parameters for the psychiatric assessment of infant and toddlers (0-36 months). American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997; 36(10 Suppl): S21S36.
46.Meisels SJ, Provence S. Screening and Assessment: Guidelines for Identifying Young Disabled and Developmentally Vulnerable Children and Their Families. Washington, DC: Zero to Three/National Center for Clinical Infants Program; 1989.
47.Gentile S. SSRIs in pregnancy and lactation with emphasis on neurodevelopmental outcome. CNS Drugs. 2005; 19(7): 623633.
48.Thapar A, Fowler T, Rice F, etal. Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. Am J Psychiatry. 2003; 160(11): 19851989.
49.Larsson HJ, Eaton WW, Madsen KK. Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status. Am J Epidemiol. 2005; 161(10): 916925.
50.Hultman CM, Sparén P, Cnattingius S. Perinatal risk factors for infantile autism. Epidemiology. 2002; 13(4): 417423.
51.Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991; 337(8746): 867872.
52.Wright TL, Hoffman LH, Davies . Lithium teratogenicity. Lancet. 1970; 24; 2(7678): 876.
53.Pennell PB, Klein AM, Browning N, etal, for the NEAD Study Group. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav. 2012; 24(4): 449456.
54.Fox AW, Diamond ML, Spiering EL. Migraine during pregnancy: options for therapy. CNS Drugs. 2005; 19(6): 465481.
55. Flunarizine. Accessed: July 14, 2013.
56.Holmes LB, Hernandez-Diaz S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol. 2012; 94(8): 599606.
57.National Institute for Health and Clinical Excellence. The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care. Accessed: July 16, 2013.
58.Campbell E, Kennedy F, Irwin B, etal. Malformation risks of antiepileptic drug monotherapies in pregnancy. J Neurol Neurosurg Psychiatry. 2013; Nov; 84(11): e2.
59.Gentile S. Lithium in pregnancy: the need to treat, the duty to ensure safety. Exp Opin Drug Saf. 2012; 11(3): 425437.
60.Vajda FJ, Graham J, Roten A, etal. Teratogenicity of the newer antiepileptic drugs—the Australian experience. J Clin Neurosci. 2012; 19(1): 5759.
61.Gentile S. Antipsychotic therapy during early and late pregnancy: a systematic review. Schizophr Bull. 2010; 36(3): 518544.
62.Kjaer D, Christensen J, Becha BH, etal. Preschool behavioral problems in children prenatally exposed to antiepileptic drugs—a follow-up study. Epilepsy Behav. 2013; 29(2): 407411.
63.Boden R, Lundgren M, Brandt L, etal. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012; 345: e7085.
64. Mayo Clinic.Epilepsy and pregnancy: what you need to know. Accessed: September 30, 2013.
65.Frederick IO, Qiu C, Enquobahrie DA, etal. Lifetime prevalence and correlates of migraine among women in a Pacific Northwest pregnancy cohort study. Headache. In press. doi: 10.1111/head.12206.
66.Wright G, Patel M. Focal migraine and pregnancy. BMJ. 1986; 293(6561): 15571558.
67.MacGregor EA. Headache in pregnancy. Neurol Clin. 2012; 30(3): 835866.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Altmetric attention score

Full text views

Total number of HTML views: 6
Total number of PDF views: 73 *
Loading metrics...

Abstract views

Total abstract views: 460 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 14th December 2017. This data will be updated every 24 hours.